Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesnt have to be that way, writes Anastasia Christianson, Ph.D.

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The companys lead program is an exenatide implant.